Grant of Interim Extension of the Term of U.S. Patent No. 7,534,790; Vernakalant Hydrochloride, 19459 [2020-07190]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 67 / Tuesday, April 7, 2020 / Notices
All catch would be attributed to the
appropriate commercial fishing quota.
For a vessel fishing on a groundfish
sector trip, all catch of groundfish stocks
allocated to sectors would be deducted
from the vessel’s sector’s annual catch
entitlement (ACE). Once the ACE for a
stock has been reached in a sector,
vessels would no longer be allowed to
fish in that stock area unless the sector
acquired additional ACE for the stock in
question. For common pool vessels, all
groundfish catch would be counted
toward the appropriate trimester total
allowable catch (TAC). Common pool
vessels would be exempt from
possession and trip limits on EFP trips
when directed for sampling by the
Center, but would still be subject to
trimester TAC closures.
If approved, the Center may request
minor modifications and extensions to
the EFP throughout the year. EFP
modifications and extensions may be
granted without further notice if they
are deemed essential to facilitate
completion of the proposed research
and have minimal impact that does not
change the scope of the initially
approved EFP request. Any fishing
activity conducted outside the scope of
the exempted fishing activity would be
prohibited.
Authority: 16 U.S.C. 1801 et seq.
Dated: April 1, 2020.
He´le`ne M.N. Scalliet,
Acting Director, Office of Sustainable
Fisheries,National Marine Fisheries Service.
[FR Doc. 2020–07218 Filed 4–6–20; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO–P–2020–0021]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,534,790;
Vernakalant Hydrochloride
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
khammond on DSKJM1Z7X2PROD with NOTICES
VerDate Sep<11>2014
18:22 Apr 06, 2020
Jkt 250001
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy,United States Patent and Trademark
Office.
[FR Doc. 2020–07190 Filed 4–6–20; 8:45 am]
BILLING CODE 3510–16–P
The United States Patent and
Trademark Office has issued an order
granting interim extension for a oneyear interim extension of the term of
U.S. Patent No. 7,534,790.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi by telephone at (571) 272–0909;
by mail marked to his attention and
addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to his attention at
SUMMARY:
(571) 273–0909; or by email to
ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On February 5, 2020, Correvio
International Sa`rl, the patent owner of
record, timely filed an application
under 35 U.S.C. 156(d)(5) for a second
interim extension of the term of U.S.
Patent No. 7,534,790. The patent claims
the human drug product, vernakalant
hydrochloride. The application for
patent term extension indicates that
New Drug Application (NDA) 22–034
was submitted to the Food and Drug
Administration (FDA) on December 19,
2006.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the once-extended
expiration date of the patent, March 31,
2020, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,534,790 is granted for a period of one
year from the extended expiration date
of the patent.
COMMODITY FUTURES TRADING
COMMISSION
Sunshine Act Meetings
1:30 p.m. EDT, Tuesday,
April 14, 2020.
PLACE: This meeting will be convened
on a telephone conference call.
STATUS: Closed.
MATTERS TO BE CONSIDERED:
Enforcement matters. In the event that
TIME AND DATE:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
19459
the time, date, or location of this
meeting changes, an announcement of
the change, along with the new time,
date, and/or place of the meeting will be
posted on the Commission’s website at
https://www.cftc.gov/.
CONTACT PERSON FOR MORE INFORMATION:
Christopher Kirkpatrick, 202–418–5964.
Authority: 5 U.S.C. 552b.
Dated: April 3, 2020.
Christopher Kirkpatrick,
Secretary of the Commission.
[FR Doc. 2020–07422 Filed 4–3–20; 4:15 pm]
BILLING CODE 6351–01–P
CORPORATION FOR NATIONAL AND
COMMUNITY SERVICE
Agency Information Collection
Activities; Submission to the Office of
Management and Budget for Review
and Approval; Comment Request;
Application Instructions for
AmeriCorps State and National
Competitive New and Continuation
Corporation for National and
Community Service (CNCS).
ACTION: Notice of information collection;
request for comment.
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995,
CNCS is proposing to renew an
information collection.
DATES: Written comments must be
submitted to the individual and office
listed in the ADDRESSES section by June
8, 2020.
ADDRESSES: You may submit comments,
identified by the title of the information
collection activity, by any of the
following methods:
(1) By mail sent to: Corporation for
National and Community Service,
Attention Arminda Pappas, 250 E Street
SW, Washington, DC 20525.
(2) By hand delivery or by courier to
the CNCS mailroom at the mail address
given in paragraph (1) above, between
9:00 a.m. and 4:00 p.m. Eastern Time,
Monday through Friday, except federal
holidays.
(3) Electronically through
www.regulations.gov.
Comments submitted in response to
this notice may be made available to the
public through regulations.gov. For this
reason, please do not include in your
comments information of a confidential
nature, such as sensitive personal
information or proprietary information.
If you send an email comment, your
email address will be automatically
captured and included as part of the
comment that is placed in the public
docket and made available on the
SUMMARY:
E:\FR\FM\07APN1.SGM
07APN1
]]>Agencies
[Federal Register Volume 85, Number 67 (Tuesday, April 7, 2020)]
[Notices]
[Page 19459]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07190]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO-P-2020-0021]
Grant of Interim Extension of the Term of U.S. Patent No.
7,534,790; Vernakalant Hydrochloride
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension for a one-year interim extension of
the term of U.S. Patent No. 7,534,790.
FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272-
0909; by mail marked to his attention and addressed to the Commissioner
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA
22313-1450; by fax marked to his attention at (571) 273-0909; or by
email to [email protected].
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On February 5, 2020, Correvio International S[agrave]rl, the patent
owner of record, timely filed an application under 35 U.S.C. 156(d)(5)
for a second interim extension of the term of U.S. Patent No.
7,534,790. The patent claims the human drug product, vernakalant
hydrochloride. The application for patent term extension indicates that
New Drug Application (NDA) 22-034 was submitted to the Food and Drug
Administration (FDA) on December 19, 2006.
Review of the patent term extension application indicates that,
except for permission to market or use the product commercially, the
subject patent would be eligible for an extension of the patent term
under 35 U.S.C. 156, and that the patent should be extended for one
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory
review period will continue beyond the once-extended expiration date of
the patent, March 31, 2020, interim extension of the patent term under
35 U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 7,534,790 is granted for a period of one year from the
extended expiration date of the patent.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy,United States Patent
and Trademark Office.
[FR Doc. 2020-07190 Filed 4-6-20; 8:45 am]
BILLING CODE 3510-16-P
